On the heels of a clinical setback for Bristol Myers Squibb’s schizophrenia newcomer Cobenfy, the New Jersey pharma is ...

A new study led by scientists from the University of Zurich and the University Hospital of Psychiatry Zurich has found a ...

Cobenfy (xanomeline and trospium chloride) as an adjunctive treatment to atypical antipsychotics demonstrated a 2.0-point ...

Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of ...

Bristol Myers Squibb & Co (NYSE:BMY) on Tuesday released topline results from the Phase 3 ARISE trial evaluating the efficacy ...

BMS has reported topline outcomes from the ARISE trial of Cobenfy as an adjunctive treatment to atypical antipsychotics for ...

Neurocrine Biosciences' valbenazine shows promise as an adjunctive therapy for Schizophrenia, with phase 3 data expected in ...

Bristol Myers Squibb's Cobenfy as an adjunctive treatment did not reach the threshold for a statistically significant difference compared to a placebo with an atypical antipsychotic in adults with ...

Regular exercise is a huge help for managing schizophrenia, but barriers like medication side effects and symptoms like fatigue and lack of motivation can make this difficult.

Research highlights the potential for modifying the chemical structures of psychedelics to produce analogues with improved ...

Study suggests accelerated brain ageing is a factor in the development of schizophrenia – and can be measured using a simple ...

Explore how LB Pharmaceuticals is revolutionizing the pharma industry with its innovative therapies for neuropsychiatric ...